Analyst Ratings For AtriCure Inc. (NASDAQ:ATRC)
Today, JPMorgan Chase & Co. initiated coverage on AtriCure Inc. (NASDAQ:ATRC) with a Overweight with a price target of $37.00.
There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on AtriCure Inc. (NASDAQ:ATRC) is Buy with a consensus target price of $35.8333 per share, a potential 28.90% upside.
Some recent analyst ratings include
- 4/12/2019-AtriCure Inc. (NASDAQ:ATRC) has coverage initiated with a Overweight rating and $37.00 price target
- 4/2/2019-AtriCure Inc. (NASDAQ:ATRC) gets upgraded to Buy by BTIG Research with a price target of $35.00
- 3/28/2019-AtriCure Inc. (NASDAQ:ATRC) had its Buy rating reiterated by Needham & Company LLC with a $39.00 price target
- 6/16/2017-AtriCure Inc. (NASDAQ:ATRC) had its Outperform rating reiterated by Leerink Swann with a $26.00 price target
- On 8/15/2018 Justin J Noznesky, SVP, sold 4,000 with an average share price of $30.32 per share and the total transaction amounting to $121,280.00.
- On 6/14/2018 Mark A Collar, Director, sold 2,090 with an average share price of $25.00 per share and the total transaction amounting to $52,250.00.
- On 5/8/2018 Elizabeth D Krell, Director, sold 10,000 with an average share price of $22.82 per share and the total transaction amounting to $228,200.00.
- On 3/13/2018 Elizabeth D Krell, Director, sold 10,000 with an average share price of $20.00 per share and the total transaction amounting to $200,000.00.
- On 3/1/2018 Regina E Groves, Director, bought 1,000 with an average share price of $17.43 per share and the total transaction amounting to $17,430.00.
- On 2/15/2018 Justin J Noznesky, SVP, sold 4,000 with an average share price of $17.03 per share and the total transaction amounting to $68,120.00.
- On 11/30/2017 M. Andrew Wade, CFO, sold 2,000 with an average share price of $18.41 per share and the total transaction amounting to $36,820.00.
About AtriCure Inc. (NASDAQ:ATRC)
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Recent Trading Activity for AtriCure Inc. (NASDAQ:ATRC)
Shares of AtriCure Inc. closed the previous trading session at 27,80 +0,15 0,54 % with 28.77 shares trading hands.